Fuchs Endothelial Dystrophy Explained — Symptoms, Progression, and Treatment

Fuchs endothelial corneal dystrophy is a progressive condition affecting the innermost layer of the cornea. It is one of the most common reasons for corneal transplantation in Australia and the United States, and is a condition I see regularly in my practice at Northern Eye Consultants in Bundoora. Understanding how the disease works and when treatment becomes necessary can help patients and their families make sense of what is often a gradually evolving clinical picture.

The role of the corneal endothelium

The cornea is the clear front window of the eye. Its clarity depends on being kept in a slightly dehydrated state — the cornea must remain relatively dry to remain optically clear. This dehydration is maintained by the corneal endothelium: a single layer of hexagonal cells lining the inner surface of the cornea, whose primary function is to pump fluid out of the corneal stroma.

Humans are born with approximately 3,000 to 4,000 endothelial cells per square millimetre. This density declines slowly with age in everyone. The cornea can tolerate quite significant reductions in endothelial cell density while maintaining normal function — problems arise when cell density falls below approximately 500 cells per square millimetre, at which point the remaining cells cannot maintain adequate fluid pumping and the cornea begins to swell.

What happens in Fuchs dystrophy

In Fuchs dystrophy, endothelial cells are dysfunctional and die at an accelerated rate compared to normal ageing. The dying cells leave behind abnormal deposits called guttae on Descemet membrane — these tiny excrescences are visible under slit-lamp examination and are a key diagnostic finding. As the cell count falls, the cornea progressively swells (oedema), causing the vision to become hazy and blurred.

The condition has a genetic basis and tends to be inherited in an autosomal dominant pattern, meaning it often runs in families. However, its severity and rate of progression vary considerably between individuals, and not all people with identifiable Fuchs changes will develop visually significant disease.

Fuchs dystrophy is significantly more common in women than men, and typically becomes symptomatic in the fifth to seventh decade of life, though endothelial changes are often detected on slit-lamp examination years or decades before vision is affected.

Symptoms and when they appear

The characteristic early symptom of Fuchs dystrophy is blurred or hazy vision that is worse in the morning and improves through the day. This happens because with the eye closed during sleep, tear evaporation is reduced, allowing the cornea to absorb more fluid overnight. On waking, the cornea is maximally swollen; as the day progresses and the eye remains open, tear evaporation carries some of that fluid away and vision partially clears.

As the condition advances, this diurnal pattern becomes less pronounced and vision remains blurred throughout the day. Glare and halos around lights are common, particularly in bright conditions or at night. In advanced cases, fluid-filled blisters (bullae) form on the corneal surface and can rupture, causing acute pain and a foreign body sensation.

Assessment and monitoring

Diagnosis is made by slit-lamp examination, which reveals the characteristic guttae. Specular microscopy measures endothelial cell density and morphology and is used to track disease progression over time. Anterior segment OCT can measure corneal thickness (pachymetry), which increases as oedema develops. In patients planning cataract surgery, endothelial cell count is a critical piece of information — cataract surgery itself stresses the endothelium and can precipitate decompensation in eyes with marginal endothelial reserve.

When is treatment needed?

Many patients with Fuchs dystrophy are monitored without intervention for years. Conservative measures — hypertonic saline drops such as Muro 128, and using a hairdryer at arm's length in the morning to evaporate surface moisture — can provide some relief in the early stages.

Surgical treatment is indicated when:

• Vision deterioration is affecting daily activities and quality of life
• Endothelial cell counts suggest the cornea will not safely tolerate planned cataract surgery
• The cornea is decompensated to a degree that conservative measures no longer provide acceptable vision

The timing of surgery, and whether it is combined with cataract surgery or performed separately, is a clinical judgement based on the individual patient's corneal status, visual needs, and lens status.

DMEK — the surgical treatment of choice

For most patients with Fuchs dystrophy requiring corneal transplantation, DMEK (Descemet Membrane Endothelial Keratoplasty) is now the preferred procedure. DMEK replaces only the diseased Descemet membrane and endothelium — a graft approximately 10 to 15 microns thick — while preserving the patient's own healthy anterior cornea.

Compared to earlier techniques such as DSAEK or full-thickness PKP, DMEK provides better visual outcomes, faster recovery, and a significantly lower rejection rate. Most patients achieve functional vision within four to six weeks and the majority of improvement is complete by three months.

For patients who also have a visually significant cataract, combined DMEK and cataract surgery allows both conditions to be addressed in a single anaesthetic — shortening the overall treatment pathway considerably.

For a detailed guide to the different types of corneal transplantation, see What Is a Corneal Transplant? DMEK, DALK, and DSAEK Explained. A comprehensive overview of corneal transplantation procedures performed by Dr MacIntyre is available at corneaeyedoctor.com/corneal-surgery/.

Consultations for Fuchs dystrophy and corneal transplantation are available at Northern Eye Consultants, Suite 5, Northpark Private Hospital, 135 Plenty Road, Bundoora, and at Bass Coast Eye Centre, Wonthaggi. To refer or book, contact (03) 9466 8822 or refer via HealthLink EDI nthneyec.